


## PHARMACEUTICAL 2019



## Enveric Biosciences Inc. Rank 234 of 371





#### PHARMACEUTICAL 2019

# ENVERIC

# Enveric Biosciences Inc. Rank 234 of 371

The relative strengths and weaknesses of Enveric Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Enveric Biosciences Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 513% points. The greatest weakness of Enveric Biosciences Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 514% points.

The company's Economic Capital Ratio, given in the ranking table, is -255%, being 76% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	10,061
Cost of Goods Sold	34,015
Intangible Assets	19,508
Liabilities, Current	14,689
Liabilities, Non-Current	4,189
Other Assets	9.4
Other Compr. Net Income	-2,533
Other Expenses	11,684
Other Liabilities	0
Other Net Income	-3,403
Property and Equipment	59
Research and Development	0
Revenues	42,998
Selling, General and Administrative Expense	10,795

Output Variable	Value in 1000 USD
Assets	29,637
Liabilities	18,878
Expenses	56,493
Stockholders Equity	10,759
Net Income	-16,898
Comprehensive Net Income	-18,164
Economic Capital Ratio	-255%